Successful completion of $30.0m financing package
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO
("Renalytix" or the "Company")
Successful completion of
Director/PDMR Dealing
The Equity Fundraise consisted of subscriptions for 2,221,794 Ordinary Shares ("New Ordinary Shares") and 103,447 American Depositary Shares ("ADSs") (the "New ADS"), at a price of
Following the completion of the Equity Fundraise and the satisfaction of the customary conditions precedent, the Convertible Bonds Fundraise has also completed.
The net proceeds of the Fundraise will be used for general working capital purposes and to support expected company growth.
Further details of the Fundraise is set out in the 31 March Announcement.
Director and Senior Management Participation
Additionally, the directors of the Company (the "Directors") and certain of its persons discharging managerial responsibility ("PDMRs") as defined under Regulation (596/2014/EU) as it forms part of domestic law in the
For further information, please contact:
|
|||
|
Via Walbrook PR |
||
|
|
||
Stifel (Nominated Adviser and Sole Financial Adviser and Sole Placement Agent) |
Tel: 020 7710 7600 |
||
|
|
||
|
|
||
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
||
|
Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 |
||
|
|
||
|
Tel: 415-389-6400 or investors@renalytix.com |
||
|
|
||
About Renalytix
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
a)
|
|
1) 2) 3) 4)
|
|||
2
|
Reason for the notification
|
||||
a)
|
Position/status
|
1) 2) Non-Executive Director 3) Non-Executive Director 4) President and PDMR
|
|||
b)
|
Initial notification /Amendment
|
Initial Notification |
|||
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
a)
|
|
|
|||
b)
|
LEI
|
213800NTOH3FK3WER551 |
|||
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
a)
|
Description of the financial instrument, type of instrument |
Ordinary shares of |
|||
|
|
||||
Identification code |
GB00BYWL4Y04
|
||||
|
|
||||
b)
|
Nature of the transaction
|
Purchase of New Ordinary Shares |
|||
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
1) |
551,724 |
|
|
|
|
2) |
27,586 |
|
|
|
|
3) |
68,964 |
|
|
|
|
4) |
55,172 |
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
||||
- Aggregated volume |
703,446 |
||||
|
|
||||
- Price |
|
||||
|
|
||||
e)
|
Date of the transaction
|
|
|||
f)
|
Place of the transaction
|
Off market |
*
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning: the expected closing of the transactions discussed in this press release, the expected use of proceeds, and the expected cash runway as a result of these transaction. Words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "seeks," and similar expressions are intended to identify forward-looking statements. We may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on our forward-looking statements. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others: that KidneyIntelX is based on novel artificial intelligence technologies that are rapidly evolving and potential acceptance, utility and clinical practice remains uncertain; we have only recently commercially launched KidneyIntelX; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in our filings with the
Solely for the purposes of the product governance requirements contained within Chapter 3 of the FCA Handbook Product Intervention and Product Sourcebook (the "
For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of the FCA Handbook Conduct of Business Sourcebook; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the New Ordinary Shares and New ADSs. Each distributor is responsible for undertaking its own target market assessment in respect of the New Ordinary Shares and New ADSs and determining appropriate distribution channels.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the